GGGraeme Greenfield

Graeme Greenfield

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Graeme Greenfield has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

    by Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin

    The therapeutic landscape of acute myeloid leukaemia (AML) has evolved beyond the classic ‘7 + 3’/DA regimen, through the approval and incorporation of targeted treatments in both front‐line and relapsed/refractory settings. Indeed, the use of selective BCL‐2 antagonists (e.g. venetoclax) and FLT3 inhibitors (e.g. midostaurin, gilteritinib) which target specific molecular characteristics of leukaemic cells, has enhanced outcomes and survival rates. Arguably one of the most exciting advancements has been the clinical development of menin inhibitors for the treatment of patients harbouring specific genetic aberrations. These abnormalities include rearrangements of the lysine methyltransferase 2A ( KMT2A ) gene, and they occur in approximately one fifth of childhood/paediatric (i.e. infant, adolescent and young adult) AML patients. Spurred on by the recent FDA approval of revumenib, menin inhibitors hold the potential to further shift the treatment paradigm for this patient population. Here, we aim to provide a comprehensive overview of the pathogenesis of KMT2A rearrangements, with a focus on KMT2A fusion genes and proteins within paediatric AML patients. Additionally, we summarise the challenges arising from resistance to menin inhibitors, and we touch on the potential of combination therapies to expand the efficacy of menin inhibition and mitigate some of the resistance mechanisms employed by leukaemic clones.


  • Top Cited Papers
    Open Access

    Molecular pathogenesis of the myeloproliferative neoplasms

    by Graeme Greenfield, Mary Frances McMullin, Ken Mills

    The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. Despite distinct clinical entities, these disorders are linked by morphological similarities and propensity to thrombotic complications and leukaemic transformation. Current therapeutic options are limited in disease-modifying activity with a focus on the prevention of thrombus formation. Constitutive activation of the JAK/STAT signalling pathway is a hallmark of pathogenesis across the disease spectrum with driving mutations in JAK2, CALR and MPL identified in the majority of patients. Co-occurring somatic mutations in genes associated with epigenetic regulation, transcriptional control and splicing of RNA are variably but recurrently identified across the MPN disease spectrum, whilst epigenetic contributors to disease are increasingly recognised. The prognostic implications of one MPN diagnosis may significantly limit life expectancy, whilst another may have limited impact depending on the disease phenotype, genotype and other external factors. The genetic and clinical similarities and differences in these disorders have provided a unique opportunity to understand the relative contributions to MPN, myeloid and cancer biology generally from specific genetic and epigenetic changes. This review provides a comprehensive overview of the molecular pathophysiology of MPN exploring the role of driver mutations, co-occurring mutations, dysregulation of intrinsic cell signalling, epigenetic regulation and genetic predisposing factors highlighting important areas for future consideration.


  • Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort

    by Olga Michail, Patrick McCallion, Julie McGimpsey, Andrew Hindley, Graeme Greenfield, Roisin McAllister, John Feerick, Claire Arnold, Nick Cross, Robert Cuthbert, et al.

    Essential thrombocythaemia (ET) is driven by somatic mutations involving the JAK2 , CALR and MPL genes. Approximately 10% of patients lack driver mutations and are referred as ‘triple-negative’ ET (TN-ET). The diagnosis of TN-ET, however, relies on bone marrow examination that is not always performed in routine practice, and thus in the real-world setting, there are a group of cases with suspected TN-myeloproliferativeneoplasm. In this real-world cohort, patients with suspected TN-ET were initially rescreened for JAK2 , CALR and MPL and then targeted next-generation sequencing (NGS) was applied. The 35 patients with suspected TN-ET had a median age at diagnosis of 43 years (range 16–79) and a follow-up of 10 years (range 2–28). The median platelet count was 758×10 9 /L (range 479–2903). Thrombosis prior to and following diagnosis was noted in 20% and 17% of patients. Six patients were JAK 2V617F and two patients were CALR positive on repeat screening. NGS results showed that 24 of 27 patients harboured no mutations. Four mutations were noted in three patients. There was no evidence of clonality for the majority of patients with suspected TN-ET with targeted NGS analysis. Detection of driver mutations in those who were previously screened suggests that regular rescreening is required. This study also questions the diagnosis of TN-ET without the existence of a clonal marker.


  • Open Access

    Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms

    by Graeme Greenfield, Suzanne McPherson, James Smith, Adam Mead, Claire Harrison, Ken Mills, Mary Frances McMullin

    Dysregulation of epigenetic processes is increasingly understood to play a role in the pathogenesis of myeloproliferative neoplasms (MPNs). Ruxolitinib, a JAK/STAT inhibitor, has proved a useful addition to the therapeutic arsenal for these disorders, but has limited disease modifying activity. We determined the effect of JAK inhibition on the histone landscape of MPN cells in cell line models of MPNs and validated using samples from the MAJIC randomised clinical trial of ruxolitinib in polycythaemia vera and essential thrombocythaemia. We demonstrated an epigenetic modifying effect of ruxolitinib using a histone modification assay. The majority of 21 histone H3 modifications were upregulated, with H3K27me3 and H3K36me2 significant in the combined cell line results. Chromatin immunoprecipitation and sequencing (CHIP-seq) for three marks of interest, H3K4me1, H3K4me3 and H3K27ac, was consistent with the histone modification assay showing a significant increase in H3K4me3 and H3K27ac peaks at promoter regions, both marks of active transcription. In contrast, RNA sequencing demonstrates a coordinated reduction in gene expression in a number of cell pathways including PI3K-AKT signalling, transcriptional misregulation in cancer and JAK-STAT signalling in spite of these histone changes. This highlights the complex mechanisms of transcriptional control within the cells which was reflected in analysis of the histone landscape in patient samples following ruxolitinib treatment.


  • Open Access

    Ruxolitinib: gaining more than intended

    by Graeme Greenfield, Mary Frances McMullin

    In this issue of Blood, Mollé et al demonstrate that on-target effects of ruxolitinib, a JAK1/2 inhibitor, reduce JAK2-mediated phosphorylation of STAT3 in the


  • Open Access

    Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat

    by Suzanne McPherson, Graeme Greenfield, Christen Andersen, Jacob Grinfeld, Hans C. Hasselbalch, Jyoti Nangalia, Ken I. Mills, Mary F. McMullin


  • A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms

    by Mark Alexander Catherwood, Roisin McAllister, Patrick McCallion, Julie Elizabeth McGimpsey, Andrew Hindley, John Feerick, Greame Greenfield, Paul Kennedy, Gary Benson, Claire Arnold, et al.


  • Open Access

    Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

    by Graeme Greenfield, Ross McMullan, Nuala Robson, Julie McGimpsey, Mark Catherwood, Mary Frances McMullin

    The BCR-ABL1 fusion gene underlying the pathogenesis of CML can arise from a variety of breakpoints. The e13a2 and e14a2 transcripts formed by breakpoints occurring around exon 13 and exon 14 of the BCR gene respectively are the most common. We undertook a retrospective audit using local laboratory database and electronic patient care records of 69 CML patients with an e13a2 or e14a2 transcript type identified in our regional population. The e13a2 group was on average significantly younger (45.0 years v 54.5 years), had a higher average white cell count (189.8 × 109/l v 92.40 × 109/l) and lower platelet count (308 × 109/l v 644 × 109/l) in comparison to the e14a2 group suggesting that these are distinct biological entities. Over an average follow-up of 33.8 months and 27.2 months for the e13a2 and e14a2 groups we observed an inferior molecular response to imatinib in the e13a2 group. A significantly lower number of patients in the e13a2 arm met European Leukemia Net criteria for optimal response at 12 months therapy (17.64% v 50.0%) and were slower to obtain deep molecular responses MR4 or MR4.5. Patients with an e13a2 transcript demonstrate an inferior molecular response to imatinib in our regional population.


  • Open Access

    Acute promyelocytic leukaemia (APML) with cryptic PML‐RARA fusion has a clinical course comparable to classical APML with t(15;17)(q24.1;q21.2) translocation

    by Graeme Greenfield, Olga Michail, Bridgin Merron, Julie McGimpsey, Mark Catherwood, Mary Frances McMullin


  • Open Access

    Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series

    by Graeme Greenfield, Mary Frances McMullin

    Splanchnic Vein Thrombosis (SVT) is strongly associated with underlying JAK2 V617F positive myeloproliferative neoplasms (MPN). Patients attending the tertiary haematology service in Northern Ireland with SVT and underlying JAK2 V617F MPN were identified by consultant staff. A retrospective audit was undertaken to examine therapeutic interventions and relevant outcomes. Descriptive statistics were used for qualitative data whilst students t-test allowed comparison of quantitative data. We report on the medium to long term follow-up of fourteen patients presenting with SVT on the basis of JAK2 V617F positive MPN. Females comprised 78.5% of the patients and there was an average age of 47.3 years at time of diagnosis. There was significant morbidity evident at diagnosis with liver transplantation attempted in all patients with Budd Chiari (n = 3), oesophageal varices present in 57.1%, ascites present in 42.8% and splenomegaly evident in 71.4%. 42.8% of patients did not exhibit classical phenotypic blood count findings for MPN at time of diagnosis. Over a median follow-up of 88.5 months (range = 8–211 months) recurrence of SVT was only documented in the setting of interventional liver procedure. Major haemorrhagic complications were recorded in 35.7% of patients and there was an association with dual anticoagulation and antiplatelet use. Recurrent thrombosis outside of the splanchnic venous system occurred in 28.5% of patients, predominantly occurring off therapeutic anticoagulation. No deaths were recorded and one transformation to myelofibrosis was seen during follow-up. Cytoreduction therapies were routinely used but had a high discontinuation rate due to cytopenias and intolerance. This analysis highlights the complexities of management of this group of patients over a period of long follow-up with a focus on the evidence behind therapeutic options.